Short Interest in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Rises By 11.9%

Share on StockTwits

Outlook Therapeutics, Inc. (NASDAQ:OTLK) was the target of a large growth in short interest in the month of November. As of November 29th, there was short interest totalling 1,510,000 shares, a growth of 11.9% from the November 14th total of 1,350,000 shares. Approximately 10.8% of the company’s shares are short sold. Based on an average daily volume of 385,000 shares, the short-interest ratio is currently 3.9 days.

Hedge funds have recently modified their holdings of the company. Cormorant Asset Management LP bought a new stake in shares of Outlook Therapeutics in the 2nd quarter worth approximately $32,000. Virtu Financial LLC bought a new stake in shares of Outlook Therapeutics in the 3rd quarter worth approximately $83,000. LVW Advisors LLC grew its position in shares of Outlook Therapeutics by 37.6% in the 3rd quarter. LVW Advisors LLC now owns 389,088 shares of the company’s stock worth $580,000 after buying an additional 106,293 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Outlook Therapeutics by 712.1% in the 2nd quarter. Vanguard Group Inc. now owns 396,001 shares of the company’s stock worth $824,000 after buying an additional 347,238 shares during the last quarter. Hedge funds and other institutional investors own 3.35% of the company’s stock.

OTLK has been the topic of a number of analyst reports. LADENBURG THALM/SH SH initiated coverage on Outlook Therapeutics in a research note on Wednesday, September 11th. They issued a “buy” rating and a $9.00 price target on the stock. Zacks Investment Research cut Outlook Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $7.79.

Outlook Therapeutics stock traded up $0.11 during trading hours on Friday, reaching $1.24. The company had a trading volume of 1,498,486 shares, compared to its average volume of 768,540. The company has a 50-day moving average price of $1.16 and a 200 day moving average price of $1.72. The firm has a market cap of $31.90 million, a price-to-earnings ratio of -0.11 and a beta of -0.75. Outlook Therapeutics has a 12-month low of $0.85 and a 12-month high of $10.96.

About Outlook Therapeutics

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.

Featured Story: Equal Weight Rating

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Founders Capital Management Sells 500 Shares of Weingarten Realty Investors
Founders Capital Management Sells 500 Shares of Weingarten Realty Investors
Founders Capital Management Has $28,000 Stock Holdings in Genworth Financial Inc
Founders Capital Management Has $28,000 Stock Holdings in Genworth Financial Inc
Comcast Co.  Stake Boosted by 10 15 Associates Inc.
Comcast Co. Stake Boosted by 10 15 Associates Inc.
10 15 Associates Inc. Has $2.27 Million Stake in Air Products & Chemicals, Inc.
10 15 Associates Inc. Has $2.27 Million Stake in Air Products & Chemicals, Inc.
10 15 Associates Inc. Has $2.86 Million Stock Holdings in CVS Health Corp
10 15 Associates Inc. Has $2.86 Million Stock Holdings in CVS Health Corp
10 15 Associates Inc. Grows Stock Holdings in Canadian Pacific Railway Ltd
10 15 Associates Inc. Grows Stock Holdings in Canadian Pacific Railway Ltd


© 2006-2020 Ticker Report